[Comment] Zoliflodacin shows benefit as an oral treatment for uncomplicated gonorrhoea

Neisseria gonorrhoeae inexorably develops resistance to antimicrobials used for treatment. The discovery of novel antimicrobials to treat gonorrhoea is a global priority and antimicrobial-resistant N gonorrhoeae has been identified as an urgent public health threat.1,2 Ceftriaxone remains the primary recommended regimen for gonorrhoea treatment globally. However, reports from China, Cambodia, Viet Nam, and the UK, among other countries, signal a rising threat to the preeminent place of ceftriaxone within the gonococcal treatment armamentarium due to decreased susceptibility to ceftriaxone and periodic ceftriaxone treatment failures, highlighting the importance of enhanced global antimicrobial surveillance to monitor resistance trends.